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Global warming is one of the most pressing issues that this planet faces. Methane 
production by methanogenic archaea plays a crucial in not only climate change, but also 
in the global carbon cycle.  Methanogenic archaea are strictly anaerobic microorganisms; 
however, it’s been shown that they have the ability to overcome brief exposure to oxygen.  
Understanding the systems that play a role in the ability of these methanogens to recover 
from transient oxygen exposure could lead to greater insight and development of strains 
that can be more readily engineered for purposes of renewable energy sources. 
 The methanogen specific vinyl-4-reductase domain-containing regulator (MsvR) 
is a transcription regulator exclusive to methanogenic archaea.  This transcription 
regulator was first discovered in Methanothermobacter thermautotrophicus (Mth) and 
was shown to regulate its own expression, as well as regulate the expression of the fpaA-
rlp-rub operon which has been implicated in response to oxidative stress.  Unlike 
MthMsvR, MsvR homologue in Methanosarcina acetivorans (MaMsvR) was not found 
to regulate an fpaA-rlp-rub operon, which raised questions as to what other roles this 
multiple domain transcription regulator may play in regulating responses to 
environmental stress.  This study attempted to look at the individual domains of MaMsvR 
utilizing MaMsvR truncations and to isolate the V4R effector domain to gain a better 
understanding of its role in regulating MaMsvR activity in addition to attempting to 
elucidate the structure of MaMsvR.  The data obtained from this study suggested that the 
V4R domain of MaMsvR contains its own dimerization interface, however, it does not 




Chapter 1:  Introduction 
 
According to information available from the Environmental Protection Agency 
(EPA), methane, a potent greenhouse gas is the second highest contributor to global 
warming.  Methane ranks second behind carbon dioxide in abundance of greenhouse 
gases, however, it is known to trap twice as much heat within the atmosphere [1].  
Methane emissions can be attributed to industry, such as oil and natural gas production 
as well as coal mining, or from biological sources mainly associated with agriculture and 
the decomposition of organic matter [1,2].  Methane production from these biological 
sources including enteric fermentation, landfills and manure management make up over 
50% of total methane production [3,4,].  An observed slight decreasing trend in overall 
methane production has been seen since 2009, however, according to the EPA, this 
decrease is due to a decline in methane production from industrial abiotic sources, while 
there has been a reported increase in methane production from biological sources 
[1,5,6,7,8].  Therefore, it is crucial to gain an understanding of biogenic methane 
production from a molecular level so as to aid in future predictions of methane 
contributions to global warming [9]. 
The primary source of biogenic methane is methanogenic archaea.  
Methanococcus, Methanobacterium and Methanosarcina are three representative genera 
from the class Euryarchaeaota are all known to generate methane as the primary product 
of their metabolisms through various and species-specific methanogenic pathways 
[10,11].  Methanogenic pathways utilize different substrates, however, regardless the 
pathway, they all generate methane as an end product and methanogenesis is their sole 
metabolic pathway for the production of energy [12,13,14].  Since methanogens play a 
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major role in the global carbon cycle by producing methane gas, which is a final step of 
the decomposition of organic matter, they are central to all life.   
Methanogens have been historically considered strict anaerobes, with an 
evolutionary history that likely precedes atmospheric oxygen.  It is known that for much 
of earth’s history anaerobic organisms were dominant.  As oxygen levels rose, life had to 
deal with not only the benefits, but also the toxic effects of oxygen.  Methanogens live in 
highly reduced environments and employ low redox potential cofactors and enzymes that 
readily react with O2 [15].  Interestingly, some methanogenic species are known to live 
in environments continuously exposed to oxygen and redox shifts [2,16].  In the case of 
some Methanosarcina species, as soon as anoxic conditions are restored, they resume 
growth and methane production [17].   
The toxic effects from oxygen exposure arise from various reactive oxygen 
species (ROS).  These reactive oxygen species are created through single electron 
reduction, or partial reduction of molecular oxygen.  These species include superoxide, 
which is known to destroy iron-sulfur clusters, hydrogen peroxide, which oxidizes thiol 
groups, both important to the structure and functions of proteins, and hydroxyl radicals 
which can damage all biological molecules, before it is finally reduced to water 
[18,19,20,21].  Identifying and characterizing the antioxidant systems in methanogens 
will provide insight into the origins and evolution of mechanisms used to combat 
oxidative stress and/or redox shifts by this unique group of organisms.  
Both aerobic and anaerobic organisms have evolved systems in which to combat 
oxidative stress, however it has been shown that many strict anaerobes contain oxidative 
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stress response proteins that differ from those found in aerobes [22,23].  Aerobes contain 
anti-oxidant enzymes such as superoxide dismutase and catalase while anaerobes 
typically do not use these enzymes because they produce molecular oxygen as an end 
product [24,25,26].  The genomes of methanogens do encode various enzymes, such as 
F420H2 oxidase, and rubrerythrin, or homologues of these enzymes that are involved in 
the detoxification of reactive oxygen species [27]. Regulation of F420H2 oxidase in 
response to oxygen exposure has been shown to play a role in the survival of various 
species of methanogenic archaea during oxidative stress [28].  Thauer’s group showed 
that some methanogens contain genomic sequences that encode homologues of oxidative 




 oxidase, which is able to use H2 to reduce O2 to 




 oxidase, an oxidative stress response protein found in 
Methanothermobacter thermautotrophicus (Mth) appears to be regulated by the 
methanogen-specific V4R domain containing regulator (MsvR) designated MthMsvR 
[29,30,31].  Genes encoded in this operon include a flavoprotein (fpaA), a rubrerythrin-
like protein (rlp) and a rubredoxin (rub).  This operon is located downstream and 
transcribed divergently from msvR.  Microarray studies showed differential expression of 
this operon when exposed to hydrogen peroxide.  In addition to the fpaA-rlp-rub operon 
being upregulated, genes that encode for thioredoxin (Trx) and thioredoxin reductase 
(TrxR), both involved in oxidative stress response, were also upregulated.  Initial studies 
of MthMsvR showed that it was responsible for regulation of the fpaA-rlp-rub operon, 
which encodes the flavoprotein homolog to F420H2 oxidase (FpaA), as well as being 
responsible for regulating transcription from its own promoter [31].   
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Archaeal transcription and its regulation share similarities to both the bacterial 
and eukaryotic domains of life.  Archaeal general transcription factors and basal 
transcription machinery is more like that seen in eukaryotes, with the archaeal RNAP 
(aRNAP) closely resembling that of RNAPII, being composed of 11-13 subunits 
[32,33,34,35].  The archaeal transcription factors that have eukaryotic homologs are 
transcription factor II b (TFB) and the TATA-binding protein (TBP)[36].  Initiation of 
archaeal transcription occurs when TBP binds to the adenine- and thymine-rich TATA box 
located approximately 25 base pairs upstream of the transcription start site (TSS)[37]. 
Once TBP has been bound to the TATA box, TFB is recruited to the promoter by TBP and 
binds the B recognition element (BRE), a purine-rich element that is located immediately 
upstream of the TATA box [38].   
Archaeal transcription regulation is more notably like that seen in bacteria.  Like 
bacterial transcription, archaeal transcription is regulated by activation or repression, in 
which an activator binds upstream or a repressor binds in close proximity of the promoter 
region.  However, far less is known about archaeal transcription activators in the archaeal 
domain compared to bacteria [39].  Similarities with bacterial transcription lie in the 
structural domains used for DNA binding in archaeal transcription regulators having a 
classic helix-turn-helix (HTH) architecture [32,40].  Transcription regulators that react to 
environmental stressors must have the ability to sense the stressed state of the cell in order 
to respond in accordance to the stress to which the cell is exposed.  For regulators 
involved in oxidative stress, once a shift in the redox state is sensed, the regulator will 
either bind to or release from the promoter region so that transcription of specific genes 
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involved in the oxidative stress response can be repressed or activated, respectively 
[41,42,43].   
Transcription regulators that act in response to oxidative stress have been well 
studied in bacteria.  Two examples of oxidative stress regulators examined in bacteria are 
OxyR and the SoxRS system [44].  OxyR is identified as a dual regulator that responds 
to the presence of hydrogen peroxide.  Genes in the OxyR regulon encode for 
glutaredoxin, glutathione reductase, NADPH-dependent alkyl hydroperoxide reductase 
HPI catalase and a DNA-binding protein (Dps), to name a few [45].  The SoxRS two-
component system responds to superoxide species and its regulon contains genes that 
encode for proteins such as ferredoxin reductase, endonuclease IV, glucose-6-P 
dehydrogenase and Mn-SOD [46,47,48].  While OxyR as well as SoxR have been shown 
to be present in cells that are not experiencing oxidative stress, their genetic responses 
and control over the aforementioned genes in times of such stress greatly contribute to 
the cells ability to resist and survive otherwise deleterious effects of oxidative agents 
[49,50]. 
The archaeal transcription factor MthMsvR has been shown to play a role in 
oxidative stress response.  Unlike MthMsvR, MaMsvR is not divergently transcribed 
from the fpaA-rlp-rub operon and its biological role and regulon are not well understood 
(Figure 1) [522].  However, it has been shown that the thioredoxin system of M. 
acetivorans converts MaMsvR between its oxidized (non PmsvR binding) and reduced 
(PmsvR binding) states suggesting it also plays a biological role in oxidative stress [51]. 
MaMsvR, like all MsvR family proteins, has an ArsR protein family winged HTH 
(wHTH) DNA binding domain at the N-terminus.  Additionally, it has a vinyl-4-reductase 
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domain located at the C-terminus that contains 3 invariant cysteine residues [522].  Initial 
characterization and comparison were performed with MthMsvR and MaMsvR [52].  An 
alignment performed on full-length MthMsvR and MaMsvR proteins revealed a 33% 
sequence identity and conserved domain organization; both having an N-terminal DNA 
binding domain, a C-terminal V4R domain, and 3 conserved cysteine residues in the V4R 
domain, which may play a role in redox sensing (Figure 2).  Two of the five cysteine 
residues located in the MthMsvR V4R domain have a CX2CX3H motif, which is 
characterized as a metal-binding motif of some redox-dependent transcription regulators 
[52].  This motif is absent from MaMsvR. 
 
Figure 1. Alignment of MsvR binding boxes and genomic context for Ma msvR. This 
figure has been adapted from a previous study [522]. (A) Alignment of binding boxes on 
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Ma PmsvR to those on Mth PmsvR/fpaA. The light blue box indicates MsvR binding box A.  
The dark blue box indicates MsvR binding box B on Ma PmsvR and the yellow boxes 
indicate binding boxes 1, 2 and 3 on Mth PmsvR/fpaA. Conserved nucleotides are shaded in 
black.  (B) Genomic context for Ma msvR. Ma msvR is flanked by MA1457 and MA1459, 
with black brackets indicating the length of each intergenic region (181 bp and 128 bp). 
Arrows represent the direction of transcription for each gene. Dashed lines indicate the 
placement of the intergenic region just upstream of Ma msvR that is zoomed into below. 
MaMsvR binding boxes A and B are represented by solid black lines on each side the 
nucleotide sequence. The TATA box is indicated by a purple box and BRE is indicated 
by a green box. The black bent arrow and +1 indicate the TSS for Ma msvR. 
 
Figure 2. Amino acid sequence alignment of MthMsvR and MaMsvR.  Identical amino 
acid residues are highlighted in black.  The N-terminal DNA binding domain is indicated 
by the navy blue box above the sequence alignment.  The C-terminal V4R domain is 
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indicated by red box above the sequence alignment.  Conserved cysteine residues are 
indicated by green boxes.  The MthMsvR cysteine residues in the CX2CX3H motif are 
designated by a purple box.  Non-conserved cysteine residues in MaMsvR are indicated 
by gray boxes.  The MJ140, a V4R domain containing and structurally characterized 
protein, predicted dimerization interface is indicated by a gold box.  
The V4R domain is present as a regulatory element in various proteins across all 
three domains of life [53,54].  The V4R domain has historically been classified as small 
molecule binding domains (SMBDs) that shows a variety of sensory functions as well as 
variable architectures [55].  In eukaryotes, V4R domains have been identified as playing 
a role in chlorophyll binding proteins that play a role in photosynthesis [56,57].  In 
bacteria, one such protein that contains a V4R domain is the dimethylphenol regulatory 
protein (DmpR).  DmpR is a transcriptional regulator that plays a role in the degradation 
of hydrocarbons [58].  This transcriptional regulator acts as an activator in response to 
the presence of aromatic compounds, thought to be sensed by the V4R effector domain 
[59,60].  The positive phenol-degrading gene regulator (PoxR) is another example of a 
bacterial transcription regulator that has been found to contain a V4R domain that 
responds to the presence of hydrocarbons, namely phenols [61].  Unlike in eukaryotic and 
some bacterial proteins that contain the V4R at the N-terminus, and other two domain 
bacterial regulator proteins that contain the V4R domain flanked by other domains on the 
N- and C- terminus , the V4R domain of MsvR is located at the C-terminus (Figure 3).   
Additionally, the V4R domain of MsvR does not appear to play a role in photosynthesis 
nor has it been shown to participate in hydrocarbon degradation.  Amino acid residues 
known to be important for phenol binding are not conserved in MsvR family proteins.  
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Since MsvR has been shown to play a role in the oxidative stress response and it contains 
a number of cysteine residues that are often integral to redox-sensing proteins, it is of 
interest to elucidate the unique role that the V4R domain may play in archaeal 
transcription regulation.   
 
Figure 3.  Variations in domain architectures between PoxR and DmpR versus MsvR.  
Red boxes indicate V4R domains.  Dark blue boxes indicate the DNA binding domains.  
The light gray box in PoxR indicates an ATPase domain and in DmpR it represents an 
enhancer binding protein (EBP) domain.  The solid black lines represent the polypeptide 









Chapter 2:  Exploration of the Effector Domain of the Vinyl-4-
Reductase Domain Containing Regulator, MsvR, a Redox Sensitive 
Transcriptional Regulator in Methanosarcina acetivorans 
 
Introduction  
MaMsvR was shown to share similarities in domain architecture with MthMsvR.  
Both MthMsvR and MaMsvR contain a C-terminal V4R domain containing three 
conserved cysteine residues and an N-terminal wHTH DNA binding domain.  M. 
thermautotrophicus showed to be a difficult organism to work with in order to study this 
novel protein for a variety of reasons [522].  The use of a methanogen with a tractable 
genetic system that contained a homologue of MthMsvR, M. acetivorans, was necessary 
for studies of MsvR protein family function. Having a robust genetic system as well as 
containing a homologue of MthMsvR, M. acetivorans was an ideal model for detailed 
studies of MsvR family proteins and further investigations into the roles of its various 
structural and functional domains.   
In previous studies that employed electrophoretic mobility shift assays (EMSAs), 
it was shown that MaMsvR demonstrated the ability to bind its own promoter (PmsvR) 
under reduced conditions, while in the presence of an oxidant no PmsvR binding was 
observed [52].  This is consistent with the notion that MaMsvR plays a role in redox-
sensing and oxidative stress response.  While there is a lack of experimental and structural 
information on MaMsvR, the DNA binding domain of MaMsvR is a well-characterized 
wHTH.  Unlike the well characterized wHTH DNA binding domain, the V4R domain 
has been noted to have variable architecture as well variable functionality [55-5661].  This 
study aims to: investigate the role that the V4R domain plays in sensing redox changes, 
execute the use of truncated proteins in order to determine the oligomerization state of 
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the V4R domain independent of the DNA binding domain under reduced and oxidized 
conditions as well as to employ structural studies to try to infer the overall structure of 
the V4R domain from MaMsvR.    
Materials and Methods 
Homology modeling and disorder prediction 
 The Protein Homology/analogY Recognition Engine v2.0 (Phyre2) was used to 
generate homology models from the primary amino acid sequence of full-length MaMsvR 
(MaMsvRFL) utilizing default restraints and a 99% confidence in modelling cut-off [62].      
Homology modeling was subsequently performed on MaMsvR V4R Constructs 1-4 
utilizing the same aforementioned method with each respective amino acid sequence.  
The .pdb files that fell within the greater than 99% confidence cut-off were obtained from 
Phyre2 inquiries and were then subjected to visualization. Visualization of all homology 
models were viewed with the PyMOL software package [63]. 
Design and generation of MaMsvR variants 
Protein secondary structure information from homology models, as well as an 
amino acid sequence alignment of MaMsvR and MJ1460 (the first vinyl-4-reductase 
domain-containing protein to be structurally characterized, PDB IDs: 2OSO, 2OSD) from 
Methanocaldococcus jannaschii were used to design truncated MaMsvR constructs 
containing various portions of the C-terminal half of the protein which contain the V4R 
domain.  Initially, four constructs were chosen arbitrarily so that two constructs 
(MaMsvRV4R1 and MaMsvRV4R2) were upstream of the predicted dimerization interface 
of MJ1460 and two constructs (MaMsvRV4R3 and MaMsvRV4R4) were downstream of the 
MJ1460 predicted dimerization interface.   
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The coding region for all constructs was amplified from pLK314 which encodes 
MaMsvRFL in a modified pQE80L series vector also encoding an N-terminal Strep-tag® 
II (Qiagen) [522].  All primers (see Table 1) were designed to create a MaMsvR V4R 
constructs which encompassed the C-terminal V4R domain and contained an N-terminal 
BamHI restriction site (5’-GGATCC-3’). Images of MaMsvRV4R1-V4R4 aligned with 
MaMsvRFL that include the polypeptide sequence and the putative MJ1460 V4R domain 
dimerization interface was rendered in Geneious v9.1.2 [64] (Figure 4).  The reverse 
primer utilized in all construct creations (LK589) annealed to the 3’ end of msvR from M. 
acetivorans as well as a C-terminal PstI restriction site (5’-CTGCAG -3’) present in 
pLK314.  Restriction enzyme recognition sites were included in order to create sticky-
end sites complimentary to the BamHI and PstI restriction sites on the backbone plasmid 
(pQE80L series vector, Qiagen) [31,522].  The corresponding coding regions were 
amplified via the polymerase chain reaction (PCR) in a thermal cycler using the following 
parameters:  initial denaturation at 98ᵒC for 30 seconds, followed by 25 cycles of 
denaturation at 98ᵒC for 10 seconds, annealing at 65ᵒC for 30 seconds, and extension at 
72ᵒC for 30 seconds and concluded with a final extension step at 72ᵒC for 5 minutes.  All 
amplifications were completed with Phusion® High-Fidelity DNA polymerase (New 
England Biolabs®) according to the manufacturer’s reaction conditions.  Amplicons were 
run on a 2.0% agarose gel that contained SYBR® Safe DNA Gel Stain (Thermo Fisher 
Scientific) alongside a 100 bp DNA ladder (Thermo Fisher Scientific) for 25 minutes at 
120 V, 350 mA at room temperature in order to confirm amplification.  The gels were 
visualized on a GelDocTM EZ-Imager (Bio-Rad).  The amplified PCR products were 
cleaned and concentrated using the Clean & Concentrator-5TM kit (Zymo Research) 
13 
 
according to manufacturer’s protocol, with a modification of 10 mM Tris buffer pH 8.0 
used to elute DNA.   Amplicons were cloned into pQE80LNS [522,65], which contains 
an N-terminal BamHI restriction site and a C-terminal PstI restriction site and encodes an 
N-terminal Strep-tag® II (5’-WSHPQFEK-3’) [66,67].  Both amplicons and vectors were 
digested using FastDigest®   BamHI and PstI (Thermo Fisher Scientific) according to 
manufacturer’s protocol.  Digestions were incubated at 37ᵒC for one hour.  Digested 
products were then cleaned and concentrated as described above for PCR products.  
Cleaned and concentrated digestion products were then ligated together using T4 DNA 
Ligase (New England Biolabs®) according to manufacturer’s protocol.  Ligations were 
incubated at room temperature for 30 minutes.  Ligation products were transformed into 
chemically competent Escherichia coli DH5α cells prepared via the Inoue method [68].  
A 100 μL aliquot of E. coli DH5α cells was thawed on ice for 30 minutes.  A 5 μL aliquot 
of the cleaned and concentrated ligation product was added to 100 μL of thawed 
competent cells on ice and they were gently stirred using the pipette tip, being careful not 
to introduce any air.  The mixture was allowed to incubate on ice for 30 minutes.  The 
mixture was heat shocked for 90 seconds in a 42ᵒC water bath and then transferred 
immediately back to ice to incubate for two minutes.  A 900 μL aliquot of sterile room 
temperature Luria Burtani (LB) broth (per liter: 10 g tryptone, 5 g yeast extract, 5 g 
sodium chloride was added to reaction and stirred gently with pipette tip.  The reactions 
were then incubated at 37ᵒC for one hour with shaking at 100 RPM.  Cells were pelleted 
via centrifugation at 14,000 RPM for 90 seconds at room temperature.  Then 800 μL of 
supernatant was removed and the pellet was re-suspended in the remaining 100 μL of 
supernatant via vortex.  The suspension was the plated on pre-warmed (to 37ᵒC) LB agar 
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plates that contained 100 μg mL -1 of ampicillin using the hockey stick method.  The 
suspension liquid was allowed to absorb into the LB agar ampicillin plates for 10 minutes 
at room temperature and then the plates were incubated overnight at 37ᵒC in an inverted 
position.  Colonies were chosen from successful transformation plates and subjected to 
colony PCR performed with GoTaq® Green DNA polymerase (Promega) according to 
manufacturer’s protocol and using respective forward primers and the reverse primer 
LK415 (Table 2).  The PCR products were run on a 1 % agarose gel containing SYBR® 
Safe DNA Gel Stain (Thermo Fisher Scientific) for 25 minutes at 120 V, 350 mA at room 
temperature in order to confirm the plasmid contained an appropriately sized DNA insert.  
Colonies that contained the insert were inoculated into 5 mL sterile LB broth containing 
100 μg mL -1 of ampicillin and incubated overnight at 37ᵒC with shaking at 250 RPM.  
Positive growth was assessed via visualization of turbidity.  Glycerol stocks were created 
for each MaMsvR variant strain (300 μL overnight culture in 700 μL 50% glycerol, 
inverted to mix, stored at -80ᵒC).  All plasmids and strains are listed in Table 2 and 3, 
respectively.  Plasmid DNA was purified from 1 mL of the remaining overnight cultures 
using ZyppyTM Plasmid Miniprep kit (Zymo Research) according to manufacturer’s 
protocol, with a modification of 10 mM Tris buffer pH 8.0 to elute plasmid DNA.  
Purified plasmids were quantified using Qubit® dsDNA Broad Range Assay Kit and the 
Qubit® fluorometer (Thermo Fisher Scientific).  Quantified plasmids were then sent to 
Oklahoma Medical Research Foundation (OMRF) DNA Sequencing Facility along with 
respective forward and reverse primers for sequence verification.  Sequence results were 
aligned against the MaMsvRFL DNA sequence in the biological sequence alignment 




Figure 4.  MaMsvRV4R1-V4R4 Constructs.  MaMsvRFL amino acid sequence above the 
MaMsvR region indicated in light gray.  The DNA binding domain is indicated by the 
navy blue bar above the amino acid sequence.  The MJ1460 dimerization interface is 
indicated by the gold bar above the amino acid sequence.  The predicted V4R domain is 
indicated by the dark red box above the amino acid sequence.  MaMsvRV4R1 is indicated 
by the longest red bar below the MaMsvR region.  MaMsvRV4R2 is indicated by red bar 
below MaMsvRV4R1.  MaMsvRV4R3 is indicated by the red bar below MaMsvRV4R2.  
MaMsvRV4R4 is indicated by the red bar below MaMsvRV4R3.  
Protein expression and purification 
Sequence confirmed plasmids were transformed as described above into lab strain E. coli 
RosettaTM cells (Novagen) which contained an inducible expression vector.  E. coli 
RosettaTM (Novagen) can also accommodate expression of proteins that contain rare 
codons for which E. coli does not have sufficient tRNAs to decode [70,71,72].  The 
transformations were performed as previously described with the addition of 100 μg mL 
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-1 chloramphenicol and 100 μg mL -1 ampicillin to all growth medium.  Transformants 
were incubated at 37ᵒC overnight with shaking at 250 RPM.  Glycerol stocks were made 
for each strain as described above.  A 10 mL aliquot of each culture was then pelleted in 
2 mL aliquots via centrifugation at 14,000 RPM, for 90 seconds at room temperature.  
The supernatant was discarded and the pellets were then re-suspended in 10 mL (2 mL 
media per 2 mL pellet) of auto-inducing media (per liter: ~928 mL sterile ZY media (10 
g tryptone, 5 g yeast extract, ~923 mL ddH2O); remaining constituents all filter sterilized; 
1 mL 1000X MgSO4 (per 100 mL: 24.65 g MgSO4 • 7H2O), 1 mL 1000X trace metals (per 
100 mL: 1.35 g FeCl3, 0.294 g CaCl2, 0.198 g MgCl2, 0.2875 g ZnSO4, 0.0476 g CoCl2, 
0.0341 g CuCl2, 0.0475 g NiCl2, 0.0484 g Na2MoO4 • 2H2O, 0.0124 g H3BO3, 0.5 mL 12 
M HCl), 20 mL 50X 5052 (per 100 mL: in order; 25 g glycerol, 73 mL ddH2O, 2.5 g 
glucose, 10 g α-lactose), 50 mL 20X NPS (per 100 mL: in order; ~50 mL ddH2O, 6.6 g 
(NH4)2SO4 , 13.6 g KH2PO4, 28.61 g Na3PO4 • 7H2O or 14.2 g Na3PO4 anhydrous, bring 
to volume with ddH2O) with the addition of 100 μg mL -1 chloramphenicol and 100 μg 
mL -1 ampicillin.  Re-suspended cells were added to ~1 L auto-inducing media and 
incubated at 37ᵒC for 5 hours then at 22ᵒC for 16 hours.   Cultures were qualitatively 
tested for levels of expression via SDS-PAGE gel.  A 1 mL sample from each induced 
culture was pelleted via centrifugation at 14,000 RPM for 90 seconds at room temperature 
and the supernatant was discarded.  The pellets were re-suspended in 100 mL sterile 
ddH2O and a 10 μL sample was added to 10 μL 2X Laemmli Sample Buffer (Bio-Rad) 
plus β-mercaptoethanol and boiled at 100ᵒC for 5 minutes.  Boiled and reduced samples 
were run on Mini-PROTEAN® TGXTM AnyKDTM pre-cast gels (Bio-Rad) at 200 V, 350 
mA, in 1X SDS running buffer (per liter: 30 g Tris base, 144 g glycine, 10 g SDS) at 
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room temperature.  Gels were then rinsed thoroughly in dH2O three times for 5 minutes 
with gentle shaking, stained in GelCode Blue (Thermo Fisher Scientific) for 60 minutes 
at room temperature with gentle shaking and then de-stained in dH2O for 60 minutes at 
room temperature with gentle shaking.  The gels were visualized on a GelDocTM EZ-
Imager (Bio-Rad).  Strains that showed usable expression levels were pelleted via 
centrifugation at 4°C, 12,000 RPM for 20 minutes.  Supernatant was discarded and like 
pellets were combined, weighed and stored at -80°C until ready for protein purification. 
 All protein constructs were purified as follows:  Harvested cells were thawed on 
ice and thoroughly resuspended in 5 mL of cold NP buffer (50 mM sodium phosphate, 
300 mM sodium chloride, pH 8.0) per gram of cell pellet.  If the proteins were prepared 
under reduced conditions, 5 mM β-Mercaptoethanol was added.  Resuspended cells were 
lysed via sonication on ice, for 10 seconds on, 30 seconds off; total on 2 minutes and 30 
seconds, two times.   Soluble and insoluble fractions were separated via centrifugation at 
4°C, 12,000 RPM for 20 minutes and the soluble fraction (lysate) was carefully 
transferred to another container and stored on ice.  Affinity chromatography purification 
using the Strep-tag® II was performed in order to obtain higher protein purity and avoid 
disruption of protein-bound metals that could occur with Ni(II) metal ion affinity 
chromatography [73,74].  High purity yields from Strep-tag® II affinity purification was 
possible due to the high affinity binding between the Strep-tag® II amino acid sequence 
and the composition of the Strep-Tactin Superflow Plus column resin (Qiagen) [66,67].  
Lysate was loaded onto an NP buffer pre-equilibrated Strep-Tactin Superflow Plus 
column (Qiagen).  The column flow through was collected in sterile 50 mL conical tubes.  
The column was washed three times with six column volumes of cold NP buffer.  The 
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column wash was collected in a sterile 15 mL conical tube.  The column was eluted six 
times with ½ column volume of cold NPD buffer (NP buffer with 2.5 mM d-
desthiobiotin).  Elutions were collected in sterile 1.5 mL Eppendorf tubes. The column 
was stripped using cold NP buffer containing 2-[4 -hydroxy-benzeneazo]benzoic acid, 
(HABA) until translucent white with cold NP buffer, and capped and stored at 4ᵒC in ~5 
mL NP buffer for later use.  A 5 μL aliquot of each purification sample was subjected to 
an SDS-PAGE gel, stained and visualized as previously described.  Fractions that 
contained the protein of interest were combined and concentrated to 600 μL in a primed 
(with sterile ddH2O) Amicon® Ultra-15 PLGC Ultracel-PL 10 kDa centrifugal filter unit 
(Millipore) at room temperature and then stored on ice.  Concentrated fractions were then 
subjected to a final clean-up step via size exclusion chromatography (SEC) on a 
SuperdexTM 200 Increase 10/300 GL column.  Increased purity and species separation is 
possible due to the composition of the resin.  The SuperdexTM 200 Increase 10/300 GL 
column is a porous resin that allows for proteins to be separated by size, with the larger 
proteins eluting first and smaller proteins eluting thereafter.  This is accomplished due 
the longer migration time through the porous column for the smaller proteins [75].  The 
column was calibrated with a protein mixture containing conalbumin (75 kDa), 
ovalbumin (43 kDa), carbonic anyhydrase (29 kDa) and ribonuclease A (13.7 kDa) 
prepared in accordance with the manufacturer’s instructions (GE Healthcare).  The 
column was then equilibrated in cold SEC buffer (150 mM NaCl, 20 mM Tris pH 8, 5 
mM β-Mercaptoethanol) on an ÄKTA pure M1 FPLC (GE Healthcare, Piscataway, NJ) 
at the University of Oklahoma Protein Production Core Facility.  Elutions were visualized 
using A280 on UNICORN software (GE Healthcare) and fractions of interest were 
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evaluated on SDS-PAGE gels as described above.  Fractions containing the protein of 
interest were pooled and concentrated as previously described for affinity purification.  
Protein was quantified using the PierceTM Coomassie Plus (Bradford) Assay Kit (Thermo 
Fisher Scientific) using a bovine serum albumin standard curve. 
DNA binding assays 
 DNA binding activity was assessed utilizing electrophoretic mobility shift assays 
(EMSA).  Proteins were tested under reduced (Dithiothreitol (DTT)) and oxidized (H2O2) 
conditions.  DNA binding reaction buffer contained 6.5 µl ddH2O, 2 µl of 10x Txn buffer 
(200 mM Tris pH 8.0, 100 mM MgCl2, 1.2 M KCl), 3 µl protein dialysis buffer (20 mM 
Tris pH 8.0 10 mM MgCl2, 200 mM KCl, 50% (v/v) Glycerol), 0.5 µl heparin (125 mg 
ml-1), and 2 µl of a 500 nM stock of a double-stranded 100-base pair (bp) fragment of 
PmsvR.  For oxidized conditions, the protein was pretreated with 100X H2O2 per protein 
concentration for 15 minutes at room temperature and an additional 100 mM H2O2 was 
added to the reaction.  For reduced conditions, no pretreatment of the protein was 
performed and DTT was added to the reaction to the final concentration of 10 mM.  
Reactions were incubated with appropriate protein at room temperature for 15 minutes 
and samples were run on a pre-run 8% tris-borate (TB) gel.  The resulting gel was stained 
with SYBR GoldTM (Invitrogen) for 30 minutes at room temperature in the dark and 
visualized on a GelDocTM EZ-Imager (Bio-Rad).  Images were inverted for display 
purposes. 
Crystallization screening 
 Crystallization screening was performed using the sparse matrix method with a 
Mosquito dispenser (TTP Labtech, Melbourn, United Kingdom) with one or more of the 
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following commercially available 96-well crystallization screens [76] : MCSG-1, MCSG-
2, MSCG-3, MCSG-4 (Microlytic), JCSG-plus, PACT premier (Molecular Dimensions), 
CSHT and/or Index (Hampton Research), each with the addition of 5 mM tris(2-
carboxyethyl)phosphine (TCEP), a reducing agent.  Initial trays were set-up as sitting-
drop vapor-diffusion with drops containing a 1:1 ratio of protein to well solution. 
Broadscreen crystallization trays were incubated at either 4°C, 16°C or room temperature.   
Crystal optimization 
 Conditions that were optimized around were from the MCSG-1 crystallization 
screen (Microlytic) wells A9 (0.2 M magnesium chloride, 25% (w/v) PEG3350, 0.1 M 
HEPES, pH 7.5, 5 mM TCEP) and C9 (0.8 M lithium chloride, 32% (w/v) PEG4000, 0.1 
M Tris, pH 8.5, 5 mM TCEP) with protein construct, MaMsvRV4R3.  Optimization trays 
were set-up as hanging-drop vapor-diffusion in 24-well crystallization trays.  One 
condition was finely adjusted per row in order to accomplish fine optimization.  
Conditions that were varied included salt concentration, precipitant concentration, protein 
concentration, pH, temperature and with or without micro-seeding (see Appendix A and 
Appendix B).  Drops were mounted on plastic coverslips (Molecular Dimensions) by 
adding protein to a drop of well solution on the plastic coverslip carefully without the 
introduction of air bubbles.  The coverslips with the well solution-protein mixture were 
then quickly inverted and placed over the respective well with vacuum grease lining the 
lip of the well.  Gentle pressure was applied to secure the coverslip in place and ensure 
an airtight seal.  An airtight seal was necessary in order to accomplish vapor diffusion 
that contributed to optimal crystallization conditions [77,78].  Trays were stored at 4°C, 
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16°C and/or room temperature in areas or incubators that were placed to avoid disruption, 
excessive motion or temperature fluctuation.   
X-ray data collection 
Initial MaMsvRV4R3 crystals were screened at room temperature at the University 
of Oklahoma Macromolecular Crystallography Laboratory using X-ray diffraction with 
an X-ray wavelength 1.54 Å and images were collected on the Pilatus 200K.  Crystals 
from drops that exhibited diffraction patterns consistent with protein were then 
cryoprotected in 18% PEG400 and flash-frozen in liquid nitrogen.  Crystals were sent to 
Stanford Synchrotron Radiation Lightsource (SSRL) and diffraction data was collected 
on BL12-2 with an X-ray wavelength 0.97945.  Initial data was processed on AutoXDS 
[79].  Data was further processed utilizing the HKL3000 software package [80]. 
Optimization of MaMsvR variants 
 Construct optimization incorporated the use of homology models and amino acid 
alignment from the initial construct design as well as amino acid sequence alignment and 
homology modeling information from the homolog PoxR from Cupriavidus necator (a 
phenol-responsive sensory domain of the transcription activator PoxR. PDB ID=5FRU).  
Several secondary structure prediction servers such as Jpred 4 
(http://www.compbio.dundee.ac.uk/jpred/), CFSSP (http://www.biogem.org/tool/chou-
fasman/) and NetSurfP (http://www.cbs.dtu.dk/services/NetSurfP/), and SWISS-
MODEL (http://swissmodelexpasy.org), all of which are available through the ExPASy 
bioinformatics resource portal (https://www.expasy.org/resources) as well as PSIPRED 
(http://bioinf.cs.ucl.ac.uk/psipred/) and SABLE (http://sable.cchmc.org/) were used in 
order to contribute to the production of constructs of varying lengths without interrupting 
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predicted secondary structures.    The optimized constructs were MaMsvRV4R5 – 
MaMsvRV4R13.  Further predictions of protein disorder to optimize MaMsvRV4R3 were 
accomplished using the SERp server from the Molecular Biology Institute at the 
University of California, Los Angeles, which predicts regions of amino acids where 
surface entropy should be reduced in order to optimize crystallization conditions [81]. 
Primers were designed, strains were created, and proteins were subjected to subsequent 
testing as described previously.   
Small angle X-ray scattering 
 MaMsvRFL and MaMsvRV4R2 construct were each dialyzed for 15 h at 4 °C into 
buffer containing 20 mM Tris pH 8.0, 50 mM sodium chloride and 0.5 mM TCEP to rid 
any remaining contaminants.  Prior to data collection samples were filtered through a 0.2 
µm syringe filter and diluted to the working concentrations. Homogenous samples are 
imperative for SAXS, as well as post dialyzed dialysis buffer to be subjected to SAXS in 
order to subtract background effects.  The samples and dialysis buffer were shipped on 
ice to SSRL BL4-2 and immediately stored at -80°C to avoid protein degradation.  The 
protein samples were diluted on-site to give a range of concentrations.  The dilutions are 
a necessary step for SAXS data processing.  Samples and dialysis buffer were shipped 
on ice to SSRL BL4-2.  Small-angle scattering data was collected on a Pilatus 300K.  
Initial data analysis was using SAXSPipe, which implements the SASTOOL program, 
all available through SSRL.  Output files are further analyzed and data merged and 
indexed using the ATSAS 2.8.0 program suite [82].  The scattering intensity was 
obtained by subtracting the scattering of the buffer blank from the sample scattering using 
the PRIMUS software.  All SAXS data was processed using GNOM, integrated in the 
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PRIMUS software, to obtain the pair distance distribution function (PDDF). The GNOM 
output was used with DAMMIF to calculate 7 ab initio dummy atom models. Models 
were averaged using DAMAVER and aligned to X-ray crystal structures using 
SUPCOMB.  Theoretical scattering curves for the MaMsvRV4R2 SAXS data were 
calculated using CRYSOL [83,82].  DAMAVER models were visualized in PyMol.  
Superimposition of the MaMsvRV4R2 homology model and the protein envelope derived 
from DAMAVER program were accomplished utilizing SUPCOMB from the ATSAS 











































































































































Table 2.  
Plasmids 
Plasmid Backbone Vector Function 
pQE80LNS N/A 
Strep-tag® II labeling and expression vector 
(Qiagen) 
pLK314 pQE80LNS 
Coding sequence for MaMsvRFL 
pLK371 pQE80LNS Coding sequence for MaMsvRV4R1 
pLK372 pQE80LNS Coding sequence for MaMsvRV4R2 
pLK373 pQE80LNS Coding sequence for MaMsvRV4R3 
pLK374 pQE80LNS Coding sequence for MaMsvRV4R4 
pLK439 pQE80LNS Coding sequence for MaMsvRV4R2-K223A, E224A 
pLK444 pZero Blunt 
TOPO 
Coding sequence for MaMsvRV4R2-K223A, E224A 
pLK463 pZero Blunt 
TOPO 
Coding sequence for MaMsvRV4R3-K223A, E224A 
pLK464 pQE80LNS Coding sequence for MaMsvRV4R3-K223A, E224A 
pLK467 pZero Blunt 
TOPO 
Coding sequence for MaMsvRV4R5  
pLK468 pQE80LNS Coding sequence for MaMsvRV4R5 
pLK469 pZero Blunt 
TOPO 
Coding sequence for MaMsvRV4R6 
pLK470 pQE80LNS Coding sequence for MaMsvRV4R6 
pLK471 pQE80LNS Coding sequence for MaMsvRV4R7 
pLK472 pZero Blunt 
TOPO 
Coding sequence for MaMsvRV4R8 
pLK473 pQE80LNS Coding sequence for MaMsvRV4R8 
pLK474 pQE80LNS Coding sequence for MaMsvRV4R9 
pLK497 pQE80LNS Coding sequence for MaMsvRV4R10 
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pLK498 PQE80LNS Coding sequence for MaMsvRV4R11 
 












None DH5α None None 
Novagen ptRNA Rosetta None Cam 
LK1341 pLK314 DH5α None Amp 
LK1354 pLK314 Rosetta Ma msvR in pQE80LNS 
Amp/ 
Cam 
LK1410 pLK371 DH5α Coding sequence for MaMsvRV4R1 Amp 
LK1411 pLK372 DH5α Coding sequence for MaMsvRV4R2 Amp 
LK1412 pLK373 DH5α Coding sequence for MaMsvRV4R3 Amp 
LK1413 pLK374 DH5α Coding sequence for MaMsvRV4R4 Amp 
LK1414 pLK371 Rosetta Coding sequence for MaMsvRV4R1 
Amp/ 
Cam 
LK1415 pLK372 Rosetta Coding sequence for MaMsvRV4R2 
Amp/ 
Cam 
LK1416 pLK373 Rosetta Coding sequence for MaMsvRV4R3 
Amp/ 
Cam 
LK1417 pLK374 Rosetta Coding sequence for MaMsvRV4R4 
Amp/ 
Cam 
LK1542 pLK444 DH5α Coding sequence for MaMsvRV4R2 -K223A, E224A Kan 
LK1549 pLK439 Rosetta Coding sequence for MaMsvRV4R2 -K223A, E224A 
Amp/ 
Cam 
LK1568 pLK463 DH5α Coding sequence for MaMsvRV4R3 -K223A, E224A Kan 
LK1569 pLK464 DH5α Coding sequence for MaMsvRV4R3 -K223A, E224A Amp 
LK1572 pLK467 DH5α Coding sequence for MaMsvRV4R5 Kan 
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LK1573 pLK468 DH5α Coding sequence for MaMsvRV4R5 Amp 
LK1574 pLK469 DH5α Coding sequence for MaMsvRV4R6 Kan 
LK1575 pLK470 DH5α Coding sequence for MaMsvRV4R6 Amp 
LK1576 pLK471 DH5α Coding sequence for MaMsvRV4R7 Amp 





Homology modeling and disorder prediction 
 Homology modeling results returned several versions of MaMsvR tertiary 
structure with slight differences based on model template utilized by Phyre2.  The best 
model prediction was based off of the template associated with PDB ID 2OSO.  This 
model covered 118 amino acid residues from MaMsvRFL (48% sequence coverage) with 
a 26% sequence identity and was modelled with 99.9% confidence (Figure 5).  There 
were 20 results that were modeled against different templates that all had a >99.5% 
confidence (Table 4).  Additional results returned showed templates which could cover 
276 amino acid residues (97% sequence coverage) with a >90% confidence.  The overall 
secondary structure predictions remained relatively consistent based off of sequence 
alignment results and secondary structure predictions for templates with a >95% 
confidence.  The N-terminal DNA binding domain is a winged helix-turn-helix, followed 
by a predicted approximate 90 residue flexible linker region that is comprised of several 
α-helices, loops and turns.  The C-terminal V4R domain is predicted to contain a single 
α-helix and a few antiparallel β-sheets, as well as a region that contains flexible loops and 
turns.  The sequence alignment and predicted secondary structure results obtained from 
Phyre2 with the highest percent confidence can be seen in Appendix C. 
Results returned from Phyre2 for templates for homology models for the MaMsvR 
V4R domain constructs (MaMsvRV4R1-MaMsvRV4R4) showed less variability in the 
number of templates with a >95% confidence.  The best model prediction for 
MaMsvRV4R1 was based off the template associated with PDB ID 2OSO.  This model 
covered 137 amino acid residues from MaMsvRV4R1 (85% sequence coverage) with a 
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23% sequence identity and was modelled with 100.0% confidence.  The best model 
prediction for MaMsvRV4R2 was based off of the template associated with PDB ID 2OSO.  
This model covered 118 amino acid residues from MaMsvRV4R2 (75% sequence 
coverage) with a 23% sequence identity and was modelled with 99.9% confidence.  The 
best model prediction for MaMsvRV4R3 was based off of the template associated with 
PDB ID 2OSO.  This model covered 100 amino acid residues from MaMsvRV4R3 (90% 
sequence coverage) with a 26% sequence identity and was modelled with 100.0% 
confidence. The best model prediction for MaMsvRV4R4 was based off of the template 
associated with PDB ID 2OSO.  This model covered 63 amino acid residues from 
MaMsvRV4R4 (89% sequence coverage) with a 25% sequence identity and was modelled 
with 99.9% confidence.  Additional results that were returned that were modeled against 
different templates with a confidence >90% were fewer compared to those returned for 
MaMsvRFL (Tables 5-8).  The homology models rendered in PyMOL showed variations 
in composition of α-helices and flexible loops (Figure 6).  However, the singular 
antiparallel β-sheet in the V4R region remained consistent with slight variation in the 
overall number of amino acid residues that incorporated into each of the β-strands that 
make up the β-sheet.  The sequence alignment and predicted secondary structure results 
obtained from Phyre2 for MaMsvRV4R1-MaMsvRV4R4 with the highest percent confidence 




Figure 5.   Homology Model of MaMsvRFL.  The homology model displayed shows 
MaMsvRFL in its monomeric state.  The N-terminus and the C-terminus are indicated with 
an N or C, respectively. The overall color scheme of the homology model of MaMsvRFL 
follows an inverse modified rainbow pattern (blue, light blue, blue-green, green, light 















(%) % Identity 
5KBH 128 52 99.8 19 
5FRU 128 52 99.7 21 
3BJ6 115 46 99.5 14 
3G3Z 113 46 99.5 22 
5ERI 110 44 99.5 15 
1LNW 107 43 99.5 11 
2ETH 99 40 99.5 23 
1LJ9 114 46 99.5 8 
4FHT 112 45 99.5 13 
1JGS 111 45 99.5 13 
1S3J 110 44 99.5 14 
3NRV 106 43 99.5 15 
3ZMD 123 50 99.5 15 
3BRO 117 43 99.5 15 
2GXG 115 46 99.5 20 
3ZPL 107 43 99.5 12 
3NQO 104 42 99.5 14 
3BPX 114 46 99.5 21 
3E6M 117 47 99.5 12 
 
 








(%) % Identity 
5KBH 153 94 99.9 18 
5FRU 128 79 99.9 21 
2KIL 129 79 98.4 16 
2NJC 147 90 98.2 12 
2O0C 128 79 98.2 17 
1U55 128 79 98.0 17 
3CUE 135 83 97.7 14 
2J3T 135 83 97.6 16 
2CFH 129 79 97.2 18 
2Z9F 103 63 96.5 21 
1WC9 131 80 94.4 13 












(%) % Identity 
5KBH 153 97 99.9 19 
5FRU 146 92 99.9 22 
2KIL 148 94 98.8 17 
2O0C 148 94 98.7 14 
1U55 148 94 98.4 18 
3NJC 147 93 98.4 14 
2J3T 135 85 97.8 19 
3CUE 134 85 97.6 14 
2CFH 129 82 97.5 18 
1WC9 127 80 97.3 18 
2Z9F 105 66 97.1 21 
2JWB 134 85 93.9 14 
 








(%) % Identity 
5KBH 109 98 99.9 20 
5FRU 109 98 99.9 22 
2NJC 106 95 98.8 13 
2KIL 108 97 98.0 17 
3CUE 110 99 97.9 15 
2J3T 110 99 97.8 13 
2O0C 107 96 97.7 13 
2CFH 110 99 97.6 15 
1U55 108 97 97.0 19 
1WC9 110 99 96.9 16 
2Z9F 76 68 96.8 22 















(%) % Identity 
5KBH 69 97 99.8 24 
5FRU 60 84 99.7 28 
2KIL 44 61 97.1 25 
2O0C 44 61 96.7 25 




Figure 6.   Homology Models of MaMsvRV4R1-V4R4.  The homology models displayed 
show the initial MaMsvR V4R domain constructs A) MaMsvRV4R1 B) MaMsvRV4R2 C) 
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MaMsvRV4R3 D) MaMsvRV4R4.  The N-terminus and the C-terminus are indicated with 
an N or C, respectively, for each of the homology models.  All homology models 
(MaMsvRV4R1 - MaMsvRV4R4) are shown in red.   
Protein expression and purification 
 Protein expression using the auto-induction method proved to be successful for E. 
coli RosettaTM (Novagen) strains LK1354, LK1414, LK1415 and LK1416 that encoded 
for MaMsvRFL, MaMsvRV4R1, MaMsvRV4R2 and MaMsvRV4R3, respectively.  Protein 
expression for E. coli RosettaTM (Novagen) strain LK1417 that produced MaMsvRV4R4 
was not successful.  The backbone of the plasmid that contained the recombinant gene of 
interest (GOI), also contained a lac operator in order to regulate gene expression.  The 
lac operator allows for high levels of protein expression by taking advantage of the natural 
inducible system with the use of glucose and lactose in the auto-induction medium.  The 
transcription of the GOI remains partially repressed in the presence of glucose.  When 
lactose is present, LacI remains unbound to the promoter and weak expression can be 
detected.  Once glucose is depleted from the auto-induction medium, cAMP is able to 
complex with CRP, lactose is able to bind LacI in order to inactivate it and allow for full 
activation of gene expression [85,86,87].  
 
 Strep-tag® II affinity purification yielded large amounts of protein at >95% purity 
for MaMsvRFL, MaMsvRV4R1 and MaMsvRV4R2.  Typical protein yields for MaMsvRFL, 
MaMsvRV4R1 and MaMsvRV4R2 were consistently upwards of 15 mg ml-1.  For 
MaMsvRV4R3 the protein yield was much lower with a typical concentration being 3 mg 
ml-1, yet still yielding high purity (Figure 7).  In order to obtain even higher purity as 
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well as assess the oligomerization state of MaMsvRV4R1, MaMsvRV4R2 and MaMsvRV4R3 
under reduced, non-reduced and/or oxidized conditions, SEC was performed on a 
SuperdexTM 200 Increase 10/300 GL column on an ÄKTA pure M1 FPLC (GE 
Healthcare, Piscataway, NJ).  The chromatograms from SEC showed that MaMsvRV4R1, 
MaMsvR V4R2 and MaMsvRV4R3 all eluted as a dimer under reduced, non-reduced or 
oxidized conditions.  Chromatograms for each MaMsvRV4R1 and MaMsvRV4R2 uniformly 
showed a sharper more intense peak at an elution that corresponded with the approximate 
molecular weight of a dimer than did that of the chromatograms for MaMsvRV4R3 
(Figures 8-10).  MaMsvRV4R3 appeared to have considerable aggregation in the sample 
which is illustrated by the significant peak at the column void volume.  Results from 
repetitive iterations of size exclusion chromatography for both MaMsvRV4R2 and 




Figure 7.  Representative SDS-PAGE gels of MaMsvRV4R2-NStrep and MaMsvRV4R3-NStrep 
Strep-Tag® II affinity purification gel images.  MaMsvRV4R2-NStrep is 19.7 kDa and 
MaMsvRV4R3-NStrep is 14.3 kDa. (A) Representative image of MaMsvRV4R2 affinity 
purification.  (B) Representative image of MaMsvRV4R3 affinity purification.  Lanes for 
both gel images (A and B) are as follows: Lane 1 shows PierceTM Unstained Protein MW 
Marker (Thermo Fisher ScientificTM), Lane 2 contains cleared lysate that was loaded onto 
the column, Lane 3 contains column flow through, Lane 4 contains column wash and 
Lanes 5-10 show each individual elution. 
Figure 8.  Representative SEC chromatogram of MaMsvRV4R1.  The standards are 
indicated in red with the correlating molecular weights above each respective peak.  The 
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MaMsvRV4R1 sample that was loaded onto the column is represented in light blue.  The 
y-axis indicates milli absorbance units (mAU) and the x-axis shows elution volume in 
milliliter (red) and fraction number (black).  
Figure 9.  Representative SEC chromatogram of MaMsvRV4R2.  The standards are 
indicated in red with the correlating molecular weights above each respective peak.  The 
MaMsvRV4R2 sample that was loaded onto the column is represented in light blue.  The 
void volume peak is labeled Vo.  The y-axis indicates milli absorbance units (mAU) and 




Figure 10.  Representative SEC chromatogram of MaMsvRV4R3.  The standards are 
indicated in red with the correlating molecular weights above each respective peak.  The 
MaMsvRV4R3 sample that was loaded onto the column is represented in light blue.  The 
void volume peak is labeled Vo.  The y-axis indicates milli absorbance units (mAU) and 
the x-axis shows elution volume in milliliter (red) and fraction number (black). 
DNA binding assays 
 In order to determine the ability of the various MaMsvR constructs (MaMsvRV4R1, 
MaMsvRV4R2 and MaMsvRV4R3) to bind PmsvR, EMSAs were performed [88].  Previous 
studies have shown that MaMsvRFL exhibited PmsvR binding under reduced conditions, 
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but did not show PmsvR binding under non-reduced or oxidized conditions [522].  The 
EMSAs were run under non-reduced conditions, reduced conditions (with the addition of 
DTT) and/or oxidized conditions (with the addition of H2O2) to assess possible differing 
PmsvR binding (shifting) behavior in vitro in response to reduced or oxidized environments.  
A 2015 study reported that a V4R protein isolated from Thermococcus onnurineus 
demonstrated the ability of the protein to contribute to DNA binding when in the presence 
of a DNA binding transcription regulator [89,90].   To test the ability of individual 
domains of MaMsvR to combine and demonstrate the ability to have DNA binding 
activity, an EMSA was also run with MaMsvRDBD3 in the presence of MaMsvRV4R2 or 
with MaMsvRDBD3 in the presence of MaMsvRV4R3, with each protein construct added in 
equal amounts.  MaMsvRDBD3 (MaMsvR residues 1-88) and MaMsvRV4R2 (MaMsvR 
residues 89-246) make up the MaMsvR polypeptide chain in its entirety.  MaMsvRDBD3 
(MaMsvR residues 1-88) and MaMsvRV4R3 (MaMsvR residues 135-246) which consist 
of each functional domain of MaMsvR but is lacking the majority of the flexible linker 
region which includes the putative dimerization interface from Methanococcus jannaschii 
MJ1460, a V4R family protein (PDB ID: 2OSO, 2OSD). Standalone MaMsvRDBD3 had 
not previously demonstrated DNA binding activity (not shown).  No DNA binding 
activity was observed for any individual MaMsvR V4R construct, nor was DNA binding 
observed when MaMsvRDBD3 and MaMsvRV4R2 or MaMsvRDBD3 and MaMsvRV4R3 were 




Figure 11.  EMSA of Ma PmsvR with MaMsvRFL, MaMsvRV4R1, MaMsvRV4R2, 
MaMsvRV4R3 under non-reduced and reduced conditions.  Each reaction contained 50 nM 
Ma PmsvR.  Reduced reactions contained 5 mM DTT.  The DNA only control lane is 
indicated with an (–).  All lanes with protein contained 1 µM of respective protein (20-





Figure 12.  EMSA of Ma PmsvR with MaMsvRFL and MaMsvRV4R2 under reduced 
conditions.  Each reaction contained 50 nM Ma PmsvR and 5 mM DTT.  The DNA only 
control lane is indicated with an (–).  The lanes which contain protein are titrated at 1 µM, 
2 µM, 4 µM and 8 µM of the indicated protein (20 to 160 fold over DNA).
Figure 13.  EMSA of Ma PmsvR with MaMsvRFL and MaMsvRV4R3 under reduced 
conditions.  Each reaction contained 50 nM Ma PmsvR and 5 mM DTT.  The DNA only 
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control lane is indicated with an (–).  The lanes which contain protein are titrated at 1 µM, 
2 µM, 4 µM and 8 µM of the indicated protein (20 to 160 fold over DNA). 
Figure 14.  EMSA of Ma PmsvR with MaMsvRV4R2 and MaMsvRV4R3 under oxidized 
conditions.  Each reaction with MaMsvRV4R2 contained 50 nM Ma PmsvR.  All reactions 
were performed with the addition of 2 µM H2O2.  The DNA only control lane is indicated 
with an (–).  The lanes containing MaMsvRV4R2 are titrated at 1 µM, 2 µM, 4 µM and 8 
µM (20- to 160-fold over DNA).  Due to protein concentration limitations, MaMsvRV4R3 
was titrated at 1 µM, 2 µM, 4 µM and 5 µM and had no Ma PmsvR added to the lanes. 
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Figure 15.  EMSA of Ma PmsvR with MaMsvRFL and MaMsvRV4R3 under oxidized 
conditions.  Each reaction contained 50 nM Ma PmsvR and 2 µM H2O2.  The DNA only 
control lane is indicated with an (–).  The lanes which contain protein are titrated at 1 µM, 
2 µM, 4 µM and 8 µM of the indicated protein (20 to 160 fold over DNA).  Due to protein 
concentration limitations, MaMsvRV4R3 was titrated at 1 µM, 2 µM, 4 µM and 5 µM. 
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Figure 16.  EMSA of Ma PmsvR with MaMsvRFL and MaMsvRDBD3 + MaMsvRV4R2 under 
reduced conditions.  Each reaction contained 50 nM Ma PmsvR and 2 µM H2O2.  The DNA 
only control lane is indicated with an (–).  The lanes which contain protein are titrated at 
1 µM, 2 µM, 4 µM and 8 µM of the indicated protein (20 to 160 fold over DNA).  The 
lanes that have both MaMsvRDBD3 and MaMsvRV4R2 contain protein in equimolar 




Figure 17.  EMSA of Ma PmsvR with MaMsvRFL and MaMsvRDBD3 + MaMsvRV4R3 under 
reduced conditions.  Each reaction contained 50 nM Ma PmsvR and 5 mM DTT.  The DNA 
only control lane is indicated with an (–).  The lanes which contain MaMsvRFL are titrated 
at 1 µM, 2 µM, 4 µM and 8 µM of the indicated protein (20 to 160 fold over DNA).  Due 
to protein concentration limitations, MaMsvRV4R3 was titrated at 1 µM, 2 µM, 4 µM and 
5 µM.  The lanes that have both MaMsvRDBD3 and MaMsvRV4R3 contain protein in 
equimolar concentrations for total protein concentration to equate to 1 µM, 2 µM, 4 µM 
and 5 µM. 
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Figure 18.  EMSA of Ma PmsvR with MaMsvRFL and MaMsvRDBD3 + MaMsvRV4R2 under 
oxidized conditions.  Each reaction contained 50 nM Ma PmsvR and 2 µM H2O2.  The DNA 
only control lane is indicated with an (–).  The lanes which contain MaMsvRFL are titrated 
at 1 µM, 2 µM, 4 µM and 8 µM of the indicated protein (20 to 160 fold over DNA).  The 
lanes that have both MaMsvRDBD3 and MaMsvRV4R2 contain protein in equimolar 




Figure 19.  EMSA of Ma PmsvR with MaMsvRFL and MaMsvRDBD3 +MaMsvRV4R3 under 
oxidized conditions.  Each reaction contained 50 nM Ma PmsvR and 2 µM H2O2.  The DNA 
only control lane is indicated with an (–).  The lanes which contain MaMsvRFL are titrated 
at 1 µM, 2 µM, 4 µM and 8 µM of the indicated protein (20 to 160 fold over DNA).  Due 
to protein concentration limitations, MaMsvRV4R3 was titrated at 1 µM, 2 µM, 4 µM and 
5 µM.  The lanes that have both MaMsvRDBD3 and MaMsvRV4R3 contain protein in 
equimolar concentrations for total protein concentration to equate to 1 µM, 2 µM, 4 µM 







 To determine what conditions are able to give rise to MaMsvR crystallization, 
sparse matrix crystal screening was performed [76].  Commercially available 96-well 
crystallization broadscreens take advantage of previously known conditions that have 
given rise to protein crystal formation on a consistent basis.  Additionally, the small 
volumes of well solution needed from the broadscreens and for the creation of drops and 
the numerous wells makes it a quick, easy and affordable way to screen many different 
conditions in order to find ones that give rise to “hits”, or formation of protein 
precipitation, phase separation or protein crystal forms that can be optimized around 
[91,92].    MCSG-1, MCSG-2, MSCG-3, MCSG-4 (Microlytic), JCSG-plus, PACT 
premier (Molecular Dimensions), CSHT and Index (Hampton Research) all have unique 
solutions for each broadscreen matrix.  Various broadscreen crystal screening trays were 
set-up for MaMsvRFL, MaMsvRV4R2 and MaMsvRV4R3, each with the addition of 5 mM 
TCEP to maintain reducing conditions, and some using the microseeding method [93,94].  
Microseeding involves the utilization of small crystalline material to seed new 
crystallization screens which eliminates the need for the formation of nucleation centers.  
Broadscreen trays for each protein were created in multiples for the purposes of 
incubating the crystal trays at different temperatures (4°C, 16°C and/or room 
temperature) as temperature can influence nucleation [95,96,97].  Trays were set-up as 
sitting-drop vapor-diffusion with drops containing a 1:1 ratio of protein to well solution.  
MaMsvRV4R3 screen in MCSG-1 (Microlytic) at room temperature was the only 
broadscreen tray to produce crystals (Figures 20 and 21).  In order to determine if the 
crystals were salt crystals or protein crystals, the MaMsvRV4R3 crystals were mounted on 
50 
 
a nylon loop and subjected to room temperature X-ray diffraction.  The X-ray diffraction 
data that was obtained from MCSG-1 (Microlytic) broadscreen crystallization tray well 
A09 showed very low resolution (~13 Å) with a diffraction pattern that was indicative of 
protein (Figure 22).  Room temperature X-ray diffraction was performed on crystals from 
MCSG-1 (Microlytic) broadscreen crystallization tray well C09 and data collected 
showed resolution lower than that of crystals from well A09, but also with a definitive 
protein diffraction pattern (not shown). 
  
 
Figure 20.  Crystals of MaMsvRV4R3 from MCSG-1 (Microlytic) broadscreen 
crystallization tray well A09 from sitting-drop vapor diffusion.  Crystals were visible on 
Day 3 of incubation at room temperature.  Well solution consisted of 0.2 M MgCl2, 25% 
(w/v) PEG3350, 0.1 M HEPES, pH 7.5, 5 mM TCEP.  Mother-liquor contained 1:1 well 




Figure 21. Crystals of MaMsvRV4R3 from MCSG-1 (Microlytic) broadscreen 
crystallization tray well C09 from sitting-drop vapor diffusion.  Crystals were visible on 
Day 4 of incubation at room temperature.  Well solution consisted of 0.8 M LiCl, 32% 
(w/v) PEG4000, 0.1 M Tris, pH 8.5, 5 mM TCEP.  Mother-liquor contained 1:1 well 






Figure 22.  Room temperature diffraction pattern from MaMsvRV4R3-Red crystals from 
MCSG-1 (Microlytic) broadscreen tray well A09.  The X-ray beam was fixed at λ 1.54 
Å.  Exposure was set at 60 seconds with 2 frames per step.  The horizontal and diagonal 
white lines are artifacts from the beam stop. 
Crystal optimization 
 
 Optimization of crystallization conditions was imperative in order to obtain 
crystals that gave rise to higher resolution from X-ray diffraction data collection [98,99].  
Optimization trays were set-up in 24-well plastic hanging drop trays.  Each tray consisted 
of well solutions that were varied around the original solution from either MCSG-1 well 
A09 or MCSG-1 well C09.  Only one constituent per row was varied, and the conditions 
optimized around were done so in a fine optimization manner (See Appendix A and 
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Appendix B)[100].  In some of the optimization trays, microseeding and macroseeding 
were employed   MaMsvRV4R3 crystals appeared in most wells from both MCSG-1 A09 
and MCSG-1 C09 optimization trays that were incubated at room temperature (Figures 
21 and 22).  The number of days before visible crystals were observed and the size of 
crystals differed, however, crystallization happened within one week consistently.  No 
crystals appeared from trays incubated at 4°C or 16°C.    
 
Figure 23.  Representative light microscope images of MaMsvRV4R3 crystals from 
optimization trials from MCSG-1 (Microlytic) broadscreen well A09.  Crystals were 
grown at room temperature in variable well solutions. A) 0.05 M MgCl2, 25% (w/v) 
PEG3350, 0.1 M HEPES, pH 7.5, 5 mM TCEP. B) 0.15 M MgCl2, 25% (w/v) PEG3350, 
0.1 M HEPES, pH 7.5, 5 mM TCEP. C) 0.25 M MgCl2, 25% (w/v) PEG3350, 0.1 M 
HEPES, pH 7.5, 5 mM TCEP. D) 0.2 M MgCl2, 12.5% (w/v) PEG3350, 0.1 M HEPES, 
pH 7.5, 5 mM TCEP. E) 0.2 M MgCl2, 16.5% (w/v) PEG3350, 0.1 M HEPES, pH 7.5, 5 
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mM TCEP. F) 0.2 M MgCl2, 20% (w/v) PEG3350, 0.1 M HEPES, pH 7.5, 5 mM TCEP.  
All mother-liquors contained 1:1 well solution to protein and all drops were microseeded.  
 
Figure 24.  Representative light microscope images of MaMsvRV4R3 crystals from 
optimization trials from MCSG-1 (Microlytic) broadscreen well C09.  Crystals were 
grown at room temperature in variable well solutions. A) 0.2 M LiCl, 32% (w/v) 
PEG4000, 0.1 M Tris, pH 8.4, 5 mM TCEP. B) 0.4 M LiCl, 32% (w/v) PEG4000, 0.1 M 
Tris, pH 8.4, 5 mM TCEP. C) 1.0 M LiCl, 32% (w/v) PEG4000, 0.1 M Tris, pH 8.4, 5 
mM TCEP. D) 0.8 M LiCl, 22.5% (w/v) PEG4000, 0.1 M Tris, pH 8.4, 5 mM TCEP. E) 
0.8 M LiCl, 25% (w/v) PEG4000, 0.1 M Tris, pH 8.4, 5 mM TCEP F) 0.8 M LiCl, 27.5% 
(w/v) PEG4000, 0.1 M Tris, pH 8.4, 5 mM TCEP. All mother-liquors contained 1:1 well 




X-Ray data collection 
 
 Attempts were made to collect better resolution X-ray diffraction data from 
various MaMsvRV4R3 crystals at the University of Oklahoma Macromolecular 
Crystallography Laboratory.  In order to aid in preserving the integrity of the protein 
crystals, cryoprotectants were tested, crystals were flash frozen in liquid N2 and the data 
was collected under a constant liquid N2 stream.  A suitable cryoprotectant and liquid N2 
was necessary in order to displace water within the protein solvent channels, thereby 
stabilizing the protein in its crystalline form, minimize radiation damage to the protein 
crystal, allow for longer exposures and maximize the number of images obtainable before 
the protein crystal became unusable [101,102].  The cryoprotectants tested were 5% (w/v) 
PEG400, 10% (w/v) PEG400, 15% (w/v) PEG400, 18% (w/v) PEG400, 5% (w/v) 
glycerol, 10% (w/v) glycerol, 15% (w/v) glycerol, 20% (w/v) glycerol as well as a 
saturated sucrose solution.  Initially, the cryoprotectants were introduced to the protein 
crystal through a series of washes in which the protein crystal is slowly introduced into 
increasing concentrations of the cryoprotectant.  This proved to dissolve the MaMsvRV4R3 
protein crystals.  The “dunk” method was then tested.  The “dunk” method directly 
introduced the protein crystal to the cryoprotectant at the final concentration and was then 
immediately flash frozen.  The “dunk” method in 18% (w/v) PEG400 proved successful 
for the cryoprotection of MaMsvRV4R3.  Data collection was unsuccessful at the OUMCL 
with the following parameters: X-ray beam was fixed at λ 1.54 Å, exposure set at 60 
seconds with 2 frames per step.  Adjustments to exposure time were made, but still 
yielded poor resolution.  Subsequent MaMsvRV4R3 crystals were cryoprotected and flash 
frozen and shipped to SSRL in a cassette that is compatible with the Stanford Automated 
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Mounting (SAM) robot.  Crystals were transferred from the cassette onto the goniometer 
by SAM, all while remaining in cryo-conditions.  The crystal was visualized and aligned 
using SSRL Web-ice software (Figure 25).  Tunable wavelengths and easily adjustable 
beam size aided in achieving better resolution.  The diffraction data collected on BL12-1 
at SSRL at λ 0.97Å was able to be processed on autoXDS software as well as in HKL3000 
which resulted in 4.24 Å resolution (Figure 26).  Images collected were integrated and 
diffraction spots were indexed in HKL3000, however, the data was not able to be 
processed further in order to obtain a valid electron density map for use in molecular 
replacement and subsequent structure solution.  The Phenix software suite was also 
utilized in order to try to obtain a useable electron density map and structure solution, but 
yielded an unsolvable solution as well.   
 
Figure 25.  Alignment of MaMsvRV4R3 crystal at SSRL BL12-1.  The protein crystal is 





Figure 26.  X-Ray diffraction pattern from MaMsvRV4R3 crystal mounted on BL12-1 at 
SSRL.  The MaMsvRV4R3 crystal diffraction pattern showed the highest resolution to 4.24 
Å. 
Optimization of MaMsvR variants 
 
 Optimization of MaMsvR V4R variants was necessary to try to obtain more 
ordered protein crystals.  Secondary structure prediction software and homology 
modeling were utilized in order to avoid interrupting predicted secondary structures (α- 
helices and β-strands) when designing new constructs (Figure 27).  The focus of the new 
MaMsvR V4R constructs was to create variants that were between the sizes of 
MaMsvRV4R2 and MaMsvRV4R3 (Figure 28-30).  Additionally, surface entropy reduction 
(SERp) was implemented in the creation of variants of MaMsvRV4R2 and MaMsvRV4R3 to 
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incorporate mutations of residues predicted to contribute to high surface entropy 
[103,104,105,106].  The prediction from the SERp server from Molecular Biology 
Institute at the University of California, Los Angeles predicted high probability surface 
entropy residues K223 and E224 for both MaMsvRV4R2 and MaMsvRV4R3 (Figure 31).  
PCR amplification was used to create MaMsvRV4R5-MaMsvRV4R11 constructs as well as 
to introduce the amino acid substitutions K223A and E224A into MaMsvRV4R2 and 
MaMsvRV4R3 as previously described with respective primers (Table 1) .  E. coli DH5α 
strains were created, sequences were confirmed and E. coli Rosetta (Novagen) expression 
strains were created. MaMsvRV4R5 – MaMsvRV4R11, MaMsvRV4R2-SERp2 and 
MaMsvRV4R3-SERp2 proteins were overexpressed via auto-induction.   Overexpression 
trials for MaMsvRV4R5 – MaMsvR9 showed expression levels less than those of 
MaMsvRV4R3 or no observable expression at all when visualized on SDS-PAGE gels as 
described above (results not shown).  MaMsvRV4R10 and MaMsvRV4R11 showed 
promising expression and were strains were stored as glycerol stocks at -80ᵒC for future 
trials as previously described (results not shown).  Protein expression levels for 
MaMsvRV4R2-SERp2 were comparable to those reported for MaMsvRV4R2, however protein 
expression levels for MaMsvRV4R3-SERp2 were lower than those for and MaMsvRV4R3.  
Protein purification was accomplished by Strep-tag® II affinity chromatography and 
further purification by SEC as performed with initial constructs.  The protein 
concentrations that resulted from SEC for both MaMsvRV4R2-SERp2 and MaMsvRV4R3-SERp2 
were much lower than that of MaMsvRV4R3, however, both proteins still eluted at the 
volume associated with dimers (chromatograms not shown).   MCSG-1, MCSG-2, 
MCSG-3 and MCSG-4 (Microlytic) broadscreen crystallization trays with the addition of 
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5 mM TCEP were set-up for MaMsvRV4R2-SERp2 and MaMsvRV4R3-SERp2 and incubated at 
either 4ᵒC, 16ᵒC or room temperature.  None of the initial crystallization screens gave rise 
to protein crystals.      
 
 
Figure 27.  Representative secondary structure prediction.  MaMsvRFL aligned against 
MJ1460 (PDB ID 2OSO) shows predicted secondary structures for MaMsvRFL rendered 
from Swiss Prot Prediction from the ExPASy software suite.  All α-helices are 





Figure 28.  MaMsvRV4R5-V4R8 Constructs.  MaMsvRFL polypeptide sequence above the 
MaMsvR region indicated in light gray.  The DNA binding domain is indicated by the 
navy blue bar above the polypeptide sequence.  The MJ1460 dimerization interface is 
indicated by the gold bar above the polypeptide sequence.  The predicted V4R domain is 
indicated by the dark red box above the polypeptide sequence.  MaMsvRV4R7 is indicated 
by the longest red bar below the MaMsvR region.  MaMsvRV4R6 is indicated by red bar 
below MaMsvRV4R7.  MaMsvRV4R5 is indicated by the red bar below MaMsvRV4R6.  
MaMsvRV4R8 is indicated by the red bar below MaMsvRV4R5. 
 
Figure 29.  MaMsvRV4R9-V4R12 Constructs.  MaMsvRFL polypeptide sequence above the 
MaMsvR region indicated in light gray.  The DNA binding domain is indicated by the 
navy blue bar above the polypeptide sequence.  The MJ1460 dimerization interface is 
indicated by the gold bar above the polypeptide sequence.  The predicted V4R domain is 
indicated by the dark red box above the polypeptide sequence.  MaMsvRV4R10 is indicated 
by the longest red bar below the MaMsvR region.  MaMsvRV4R12 is indicated by red bar 
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below MaMsvRV4R10.  MaMsvRV4R11 is indicated by the red bar below MaMsvRV4R12.  
MaMsvRV4R9 is indicated by the red bar below MaMsvRV4R11. 
 
Figure 30.  MaMsvRV4R13-V4R15 Constructs.  MaMsvRFL polypeptide sequence above the 
MaMsvR region indicated in light gray.  The DNA binding domain is indicated by the 
navy blue bar above the polypeptide sequence.  The MJ1460 dimerization interface is 
indicated by the gold bar above the polypeptide sequence.  The predicted V4R domain is 
indicated by the dark red box above the polypeptide sequence.  MaMsvRV4R14 is indicated 
by the longest red bar below the MaMsvR region.  MaMsvRV4R15 is indicated by red bar 




Figure 31.   Homology Model of MaMsvRV4R2-SERp2.  The homology model displayed 
shows MaMsvRV4R2-SERp2 with the V4R2 portion shown in dark green and residues 
K223 and E224 depicted in slate and labelled, respectively.   
Small angle X-Ray scattering 
 In order to obtain structural information for MaMsvRV4R2, small angle X-ray 
scattering (SAXS) was employed.  SAXS takes advantage of small angle diffraction 
patterns from a large number of protein molecules in solution (107).  It is, however, 
imperative that the molecules within the solution are invisible to each other.  The protein 
samples that were prepared were purified via Strep-tag® II affinity chromatography and 
size exclusion chromatography as previously described.  High protein concentrations and 
low protein concentrations both give rise to unique artifacts during data collection that 
can subsequently be visualized on the produced scattering curves and then averaged out 
during data processing.  Output files that were generated with SAXSPipe further analyzed 
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and data merged and indexed using the ATSAS 2.8.0 program suite [82].  After 
subtracting the dialysis buffer scattering factor from the sample scatter in PRIMUS, the 
scattering intensity was calculated.  All SAXS data was processed using GNOM and then 
integrated in the PRIMUS software, to obtain the pair distance distribution function 
(PDDF). Atomic models were created with DAMMIF and then averaged together with 
DAMAVER.  The averaged models were then aligned with known structures or 
homologues in SUPCOMB.  This data was further analyzed in CRYSOL to generate the 
theoretical scattering curves [82].  After artifacts from high and low protein concentration 
data were subtracted from the average of all MaMsvRV4R2 theoretical scattering curves, 
subsequent DAMAVER models were created by repeating the aforementioned GNOM 
through DAMAVER processes. The damaver.pdb file that was generated in ATSAS was 
then opened in PyMoL to create protein envelope model.  A monomeric homology model 






Figure 32. MaMsvRV4R2 monomeric homology model superimposed onto the 
MaMsvRV4R2 protein envelope.  The protein envelope was rendered in PyMOL and 
visualized in mesh display and the monomeric MaMsvRV4R2 homology model was 
created with Phyre2.  Results were then superimposed onto the protein envelope. 
Discussion 
MaMsvR consists of an N-terminal wHTH DNA-binding domain and a C-
terminal V4R effector domain.  Each domain had a predicted dimerization interface.  
Therefore, we utilized protein truncations to identify whether a dimerization interface 
was present in the V4R and linker region of MaMsvR.  Size exclusion chromatography 
experiments infer that the V4R domain is a dimer in its oligomeric state under reduced, 
non-reduced and oxidized conditions.  Additionally, these results showed that MaMsvR 
V4R does not contain the same dimerization interface as identified in the MJ1460 V4R 
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structure (PDB ID: 2OSO, 2OSD).  Had the dimerization interface for the V4R region of 
MaMsvR been the same that was identified for the MJ1460 V4R domain, it would be 
expected that MaMsvRV4R3 would not form a dimer under any of the conditions tested.  
However, MaMsvRV4R3 was able to dimerize indicating that additional residues, C-
terminal to the region used for dimerization of MJ1460, are important for dimerization of 
MaMsvR.  The lower protein yields observed for MaMsvRV4R3 are likely because the 
position of the truncation may have interrupted a critical secondary structure element that 
resulted in lower solubility and/or stability of the protein during expression.     
Electrophoretic mobility shift assays with the V4R domain alone as well as when 
combined with the DNA binding domain did not result in DNA binding under reduced 
conditions.  This differs from MaMsvRFL which has been shown to bind PmsvR in previous 
studies [522].  Despite MaMsvRDBD3 and MaMsvRV4R2 constituting the entire length of 
the MaMsvR protein, our data indicates that these regions must be connected to obtain 
the proper protein configuration to achieve DNA binding.  This is contrast to another 
transcription regulator that is able to interact with a free V4R domain protein to exercise 
transcriptional response [89].    
While X-ray crystallography experiments were able to produce protein crystals as 
well as diffractions patterns, none were at a resolution high enough in order to solve the 
structure.    Pursuing additional constructs designed in this study may be instrumental to 
obtaining a stabilized and well-diffracting crystal to use for protein structure 
determination.  While many crystal trials were attempted, there are still parameters that 
could be tested.  What is evident from the crystallization experiments is that the protein 
continues to maintain some disorder.  As a putative effector domain of an oxidative stress 
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protein, this could be attributed to slight variations in its oxidation state that may occur 
through not only the purification steps, but also, through fluctuation of the redox state 
during the crystallization process. Results from SAXS confirmed that MaMsvRV4R2 exists 
as a dimer and provided a protein envelope in which a dimerized homology model of 
MaMsvRV4R2 was able to be superimposed.  This study concludes that MaMsvR V4R 
contains its own dimerization interface and is unable to contribute to DNA binding in 
response to the redox state of the cell unless it is as the complete, continuous MaMsvRFL. 
 Concurrent work done investigating the cysteine residues in MaMsvR concluded 
that the only three cysteine residues that fall within the disulfide bond formation cutoff 
are the three conserved cysteine residues in the V4R domain (C206, C232 and C240) [52, 
Karr Lab unpublished].  This was important because it showed that those three cysteine 
residues may play a role in redox sensing; however, whether or not these disulfide bonds 
were inter- or intramolecular disulfide bonds has yet to be determined.  Additional 
experiments not discussed in this thesis did show that zinc was present in MaMsvRV4R3 
protein crystals.  However, due to high-probability of zinc contamination, more-in depth 
analysis would have to be completed in order to identify conclusively if, in fact, zinc is 
bound in the V4R domain, under what conditions zinc binds in addition to mutagenesis 
experiments to identify what residues may play a role in zinc binding.  Further 
experiments are necessary in order to detail the exact contributions of the V4R domain in 
response to oxidative stress and the way in which it senses the shift in the redox state of 
the cell and/or facilitates a conformational change in concert with the DNA binding 
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